• $390.5M
    Market Cap
  • 70.43%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
2.7M
+106.62%
1.3M
+16.90%
1.1M
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
2.7M
+106.62%
1.3M
+16.90%
1.1M
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-57.6M
+178.30%
-20.7M
-5.25%
-21.9M
+290.81%
-5.6M
-87.82%
Depreciation and Amortization Expense
64,000
+64.10%
39,000
+333.33%
9,000
-75.00%
36,000
0.00%
Total Operating Expenses
70.7M
+93.04%
36.6M
+12.67%
32.5M
+133.78%
13.9M
-35.33%
Operating Profit
-70.7M
+93.04%
-36.6M
+12.67%
-32.5M
+133.78%
-13.9M
-35.33%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
2.3M
+1,320.53%
-190,000
+66.67%
-114,000
-770.59%
17,000
+107.66%
Income before Taxes
-68.3M
+86.71%
-36.6M
+12.67%
-32.5M
+133.78%
-13.9M
-35.33%
Income Taxes
1.0M
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-69.4M
+95.54%
-35.5M
+12.71%
-31.5M
+126.79%
-13.9M
-36.07%
Net Income from Continuing Operations Applicable to Common
-68.3M
+92.62%
-35.5M
+12.71%
-31.5M
+126.79%
-13.9M
-36.07%
Basic EPS and Net Income
-4.71
-61.30%
-12.17
+1,117.00%
-1.00
+25.00%
-0.80
-48.39%
Diluted EPS and Net Income
-4.71
-61.30%
-12.17
+1,117.00%
-1.00
+25.00%
-0.80
-48.39%
Basic Weighted Average Shares
N/A
N/A
N/A
N/A
N/A
N/A
17.4M
+24.45%
Diluted Weighted Average Shares
N/A
N/A
N/A
N/A
N/A
N/A
17.4M
+24.45%
Balance Sheet
Cash and Cash Equivalents
77.0M
+245.97%
22.2M
-40.08%
37.1M
-9.67%
41.1M
-2.25%
Short-Term Investments
36.1M
0.00%
36.1M
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
113.1M
+93.74%
58.4M
+57.21%
37.1M
-9.67%
41.1M
-2.25%
Total Current Assets
80.6M
+31.37%
61.3M
+60.06%
38.3M
-7.67%
41.5M
-2.37%
Accumulated Depreciation
112,000
+133.33%
48,000
+433.33%
9,000
N/A
N/A
N/A
Property and Plant and Equipment and Net
129,000
+67.53%
77,000
-29.36%
109,000
N/A
N/A
N/A
Total Long-Term Assets
2.1M
+1,393.48%
138,000
-74.63%
544,000
+11.93%
486,000
-38.17%
Total Assets
82.8M
+34.47%
61.6M
+57.93%
39.0M
-7.18%
42.0M
-3.02%
Income Taxes Payable
1.0M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
20.8M
+128.51%
9.1M
+147.71%
3.7M
+15.32%
3.2M
+80.83%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Liabilities
21.8M
+139.93%
9.1M
+147.71%
3.7M
+15.32%
3.2M
+80.83%
Retained Earnings
-223.4M
+45.05%
-154.0M
+29.93%
-118.5M
+36.16%
-87.0M
+18.97%
Total Stockholders Equity
61.0M
+16.22%
52.5M
+48.61%
35.3M
-9.03%
38.8M
-6.57%
Total Shares Outstanding
12.9M
+102.53%
6.4M
-82.40%
36.3M
+73.02%
21.0M
+42.33%
Cash Flow
Cash from Operating Activities
-50.9M
+65.50%
-30.7M
+7.10%
-28.7M
+250.71%
-8.2M
-50.92%
Capital Expenditures
116,000
+213.51%
37,000
-57.95%
88,000
N/A
N/A
N/A
Cash from Investing Activities
36.2M
+200.67%
-36.0M
-76,680.85%
47,000
N/A
N/A
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
69.4M
+33.75%
51.9M
+110.08%
24.7M
+240.89%
7.2M
+16,556.82%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
-2,602.47%
-6.57%
-2,785.54%
-3.62%
-2,890.21%
N/A
N/A
N/A
Return on Assets
-96.13%
+36.21%
-70.57%
-9.22%
-77.74%
+138.90%
-32.54%
-21.64%
Return on Equity
-122.28%
+51.29%
-80.82%
-4.83%
-84.92%
+145.86%
-34.54%
-20.03%
Revenue Growth
106.62%
+530.75%
16.90%
N/A
N/A
N/A
N/A
N/A
Current Ratio
3.88
-42.51%
6.76
-35.38%
10.45
-19.94%
13.06
-46.01%
Cash Ratio
3.71
+51.40%
2.45
-75.81%
10.13
-21.67%
12.93
-45.94%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow